
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is a promising company with a diverse product pipeline and a unique precision medicine platform, SNAP, which could drive success in the competitive biotechnology market. Market research and analyst predictions suggest strong potential for TYRA and dabogratinib, both of which have shown promising data in their respective indications and could generate significant peak sales. However, risks of delays and negative clinical data should be considered before investing in the company.
Bears say
Tyra Biosciences is a clinical-stage biotechnology company with a promising yet unproven precision medicine platform that targets Fibroblast Growth Factor Receptor (FGFR) biology. While the company's approach may offer potential for targeted treatments in various diseases, its current drug candidates have shown potential safety risks and may face significant competition in the market. Additionally, the company's financials suggest a need for additional funding in the near future, which adds risk to the valuation of the stock.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares